Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetesopen access
- Authors
- Lee, Seungah; Lee, Dong Yun
- Issue Date
- Mar-2017
- Publisher
- KOREAN SOC PEDIATRIC ENDOCRINOLOGY
- Keywords
- Type 2 diabetes; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; GLP-1R agonist; GLP-1R agonist clinical trials
- Citation
- ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, v.22, no.1, pp.15 - 26
- Indexed
- KCI
- Journal Title
- ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
- Volume
- 22
- Number
- 1
- Start Page
- 15
- End Page
- 26
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4805
- DOI
- 10.6065/apem.2017.22.1.15
- ISSN
- 2287-1012
- Abstract
- The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic beta-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.
- Files in This Item
-
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.